Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd

₹ 607 -6.17%
22 May - close price
About

Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals[1]

Key Points

Business Overview:[1]
SGRL is an ISO 14001 certified complex chemical manufacturer, specialising in pharmaceutical intermediates and speciality chemicals.

  • Market Cap 779 Cr.
  • Current Price 607
  • High / Low 950 / 573
  • Stock P/E 33.8
  • Book Value 113
  • Dividend Yield 0.00 %
  • ROCE 19.5 %
  • ROE 17.3 %
  • Face Value 10.0

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2020 Dec 2020 Jun 2021 Sep 2021 Dec 2021 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
11.52 13.26 12.63 16.97 21.13 37.33 24.78 32.33 27.05 24.43
7.31 10.08 9.58 12.52 15.36 20.39 16.65 21.02 17.14 14.55
Operating Profit 4.21 3.18 3.05 4.45 5.77 16.94 8.13 11.31 9.91 9.88
OPM % 36.55% 23.98% 24.15% 26.22% 27.31% 45.38% 32.81% 34.98% 36.64% 40.44%
0.45 0.54 1.11 0.44 0.88 1.32 0.54 0.19 0.71 2.29
Interest 0.01 0.02 0.07 0.03 0.03 0.15 0.32 0.44 0.39 0.97
Depreciation 0.64 0.22 0.82 0.95 0.99 1.86 2.02 2.42 2.70 2.42
Profit before tax 4.01 3.48 3.27 3.91 5.63 16.25 6.33 8.64 7.53 8.78
Tax % 22.94% 20.40% 28.75% 22.76% 25.40% 22.46% 26.70% 25.81% 27.89% 24.83%
3.09 2.77 2.34 3.02 4.20 12.59 4.65 6.41 5.42 6.59
EPS in Rs 2.41 2.16 1.83 2.36 3.28 9.84 3.62 4.99 4.22 5.13
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
35 64 49 126 109
26 52 35 84 69
Operating Profit 9 13 14 42 39
OPM % 25% 20% 28% 33% 36%
1 4 2 3 4
Interest 0 1 0 1 2
Depreciation 1 2 3 6 10
Profit before tax 9 14 13 38 31
Tax % 28% 23% 25% 26% 26%
6 10 10 28 23
EPS in Rs 4.88 8.18 7.62 21.96 17.97
Dividend Payout % 18% 13% 18% 2% 0%
Compounded Sales Growth
10 Years: %
5 Years: 11%
3 Years: %
TTM: -14%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: %
TTM: -18%
Stock Price CAGR
10 Years: %
5 Years: 62%
3 Years: 32%
1 Year: 2%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
Equity Capital 9 9 13 13
Reserves 25 33 109 132
1 4 36 38
7 9 12 8
Total Liabilities 41 55 171 192
14 20 81 95
CWIP 0 0 17 8
Investments 4 3 5 18
23 32 69 70
Total Assets 41 55 171 192

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
-5 5 3 30 31
-0 -3 -1 -33 -36
-0 -0 -1 10 -1
Net Cash Flow -5 1 2 7 -6

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2024 Mar 2025
Debtor Days 101 101 59 75
Inventory Days 125 61 156 224
Days Payable 75 43 51 61
Cash Conversion Cycle 151 119 164 238
Working Capital Days 149 115 110 202
ROCE % 35% 20%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.12% 68.27% 68.27% 69.34% 69.34% 69.33% 69.33% 69.33% 69.33% 70.49% 72.80% 72.80%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01%
30.88% 31.73% 31.72% 30.67% 30.66% 30.67% 30.66% 30.67% 30.66% 29.50% 27.19% 27.20%
No. of Shareholders 5,4655,8436,4726,7476,4077,3307,5187,0497,1868,5088,6958,978

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents